Amar Patel, MD
Interventional Cardiology · Marietta, GANPI 1750402491
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Boston Scientific at 43.7% of the total. Reporting peaked in 2019 at $26,626 and has fallen 83.0% since, to $4,514 in 2025.
Across 790 payments — averaging $91.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$32K
- Medtronic$17K
- Abbott$13K
- Edwards Lifesciences$6K
- Pfizer$1K
- Shockwave Medical, Inc$819
- plus $3K from 29 others
Across 169 payments — averaging $6108.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$575K
- Abbott$437K
- Medical Device Business Services, Inc.$19K
- Medtronic$2K
Across 2 payments — averaging $326,772 each. An ownership or investment interest held by the physician or an immediate family member.
- Corvista Health, Inc.$654K
What the payments were for
- Consulting fees$1,0001%
- Speaking & faculty fees$23,81333%
- Grants$890%
- Travel & lodging$18,68326%
- Food & beverage$28,21739%
- Education$8401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 252 | $31,737 |
| Medtronic(2 entities) | 136 | $17,276 |
| Abbott | 175 | $12,769 |
| Edwards Lifesciences | 137 | $5,681 |
| Pfizer | 10 | $1,020 |
| Shockwave Medical, Inc | 11 | $819 |
| W. L. Gore & Associates, Inc. | 8 | $558 |
| Abiomed | 9 | $485 |
| Cvrx, Inc. | 2 | $344 |
| Corvista Health, Inc. | 1 | $222 |
| Philips North America LLC | 3 | $197 |
| Livanova USA, Inc. | 3 | $186 |
| Siemens Medical Solutions USA, Inc. | 2 | $152 |
| Heartflow, Inc. | 1 | $150 |
| Novartis | 6 | $136 |
| Steris Corporation | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 7 | $123 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $105 |
| Stryker | 1 | $79 |
| Johnson & Johnson(2 entities) | 3 | $57 |
| Cardiva Medical, Inc. | 2 | $45 |
| Amgen | 2 | $43 |
| Boehringer Ingelheim | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $32 |
| Recor Medical Inc | 1 | $32 |
| Catalyst Pharmaceuticals, Inc. | 1 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Astellas Pharma US Inc | 1 | $26 |
| AbbVie | 1 | $24 |
| Penumbra, Inc. | 1 | $23 |
| Cardiac Dimensions, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| La Jolla Pharmaceutical Company | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| United Orthopedics LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$19,378
- COREVALVE EVOLUT R$12,148
- GENERAL - THERAPIES$5,467
- AMPLATZER Occluders$2,949
- Mitra Clip system$2,289
- MitraClip$1,089
- CoreValve Evolut$955
- Tendyne Mitral Valve System$921
- Resolute$839
- WATCHMAN Access System$651
- SAPIEN 3 Ultra RESILIA$593
- AMPLATZER AMULET$548
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$539
- ONYX FRONTIER$424
- Barostim Neo System$344
- Edwards SAPIEN 3 Transcatheter Heart Valve$340
- AVVIGO Guidance System$331
- Impella$284
- CARDIOFORM Septal Occluder$279
- GENERAL - STENTS$277
How this compares
$72,642 in reported general payments places this provider in the 85th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 34 | $315 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Marietta
- Salvatore ManninoMarietta$275K
- Paul GuichardMarietta$260K
- Ahmed Al BadriMarietta$110K
- Arthur ReitmanMarietta$106K
- Ateet PatelMarietta$24K
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Megan CoylewrightCalhoun$271K
- Adam GreenbaumAtlanta$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.